However, no sufficient data are available about the potential benefits of GLP-1R agonists on the regression of fibrosis and the prevention of the progression of steatosis to MASH and cirrhosis [247]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.